CompletedNCT06285916
A Study to Assess the Efficacy, Safety, and Tolerability of Oral NORA520 in Adults With Severe Postpartum Depression
Medication studyAges 18–45United States
Understand this study
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 45 years. Other eligibility criteria applied.
- Listed locations
- Bentonville and 17 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: March 28, 2024
- Recruitment status
- Completed
- Enrollment listed in the registry
- 93
- Sponsor
- TWi Biotechnology, Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 45 Years
- Official registry ID
- NCT06285916
- Official title
Show the full official title
A Randomized, Placebo-Controlled, Double-Blinded, Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Oral NORA520 in Female Adults With Severe Postpartum Depression
Get this study by email
Recruitment & locations
CompletedBentonville · Anaheim · Canoga Park
15 more locations
- Sherman Oaks
- Torrance
- Miami
- Miami Gardens
- Orlando
- Pompano Beach
- St. Petersburg
- Atlanta
- Decatur
- Savannah
- Chicago
- Glen Oaks
- Monroe
- League City
- Richardson
Questions about this study
Who is behind this study?
The study sponsor is TWi Biotechnology, Inc.
Did this study involve medication?
Yes. The study involved medication, including NORA520 Dose 1, NORA520 Dose 2 and Placebo.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 45 years. Other eligibility criteria applied.
